摘要
Liver cancer is a frequently occurring malignancy with a poor prognosis and a high mortality rate and is the second leading cause of cancer-related deaths[1]. Many chemotherapeutic drugs are extensively used to treat liver cancer, such as doxorubicin and cisplatin. However, these drugs have shown poor treatment effects in clinical trials because of acquired resistance and the high heterogeneity of liver cancer[2]. Therefore.
基金
supported by Shanxi Province Science Foundation for Youths[No.20210302124668]
the Science Research Start-up Fund for Doctor of Shanxi Province[No.SD2115]。
